Mostra tutti

Poster ▸ Antiretroviral therapy

P 1

HIV-1 RNA levels in semen of people on “short-cycle” antiretroviral therapy

P 2

Efficacy and safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in people living with HIV-1 aged over 65 years

P 3

Real-world data on the effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people living with HIV (PLWH): 24-month results of the Italian BICSTaR cohort

P 4

Probability of starting 2DR vs 3DR regimens in ART-naïve and ART-experienced PLWH before and after the COVID-19 pandemic

P 5

Physical activity, oxidative stress and antiretroviral therapy in people living with HIV: a multidisciplinary pilot study in people switching to double therapy

P 6

Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in a pregnant woman with drug resistant HIV-1 infection: A case report

P 7

To enDORse Doravirine use in antiretroviral treatment?

P 8

Effectiveness of dolutegravir/lamivudine versus tenofovir alafenamide/emtricitabine/bictegravir in a real-life cohort of HIV-1 virologically suppressed treatment experienced patients

P 9

Immuno-virological stability in patient with Multi-drug-Resistent HIV and history of poliallergy and intolerance to several antiretroviral drugs

P 10

Long-acting cabotegravir-rilpivirine in highly experienced PLWHIV: the role of Directly Observed Treatment (DOT) in overcoming barriers to adherence

P 11

Satisfaction, clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in a real-life cohort of people living with HIV

P 12

Clinical and economic evaluation of dual therapies in cART-experienced HIV positive patients

P 13

HIV-DNA trend in ART-experienced PLWH switching to injectable long-acting antiretroviral therapies with CAB+RPV: 12-week results in a real-life setting

P 14

Efficacy and safety of a switch to doravirine and dolutegravir combination in HIV-1-infected patients in a single Italian center: a cohort data analysis

P 15

Comparing efficacy, safety, and tolerability of 3TC/DTG, TAF/3TC/DOR, and TAF/FTC/BIC in switch strategy of virologically suppressed HIV-infected people

P 16

Risk of failure in dual therapy versus triple therapy in viro-suppressed HIV patients switched to CAB or DTV dual regimens: a systematic review and meta-analysis

P 17

Significant CD4+ T-cell increase in Women Living With HIV (WLWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): multi-center real-world retrospective longitudinal study

P 18

Virological rebound and the use of dietary supplements in people living with HIV: results of a survey

P 19

INSTI resistance mutations emerging while on DTG/3TC dual therapy

P 20

Real-life experience of doravirine-based regimens in a cohort living with HIV

P 21

Efficacy and safety of dolutegravir/lamivudine in a patient with HIV following sleeve gastrectomy

P 22

A retrospective cohort analysis to evaluate the barriers and facilitators encountered by HIV-positive patients undergoing HAART regimen and clinical outcomes

P 23

Fostemsavir, a new antiretroviral molecule for the treatment of heavily treatment-experienced (HTE) PLWH with multi-drug resistant (MDR) HIV-1 infection: data from clinical practice

P 24

Experience with the use of prolonged-release injectable CAB/RPV in outpatients

P 25

Efficacy, tolerability, safety and adherence to dolutegravir/lamivudine as first-line regimen in the real life setting

P 26

Acceptability of long-acting injectable antiretroviral therapy (LAI-ART) in people living with HIV

P 27

Will Lenacapavir save us? Compassionate use in heavily treatment-experienced patients with multi-drug resistant HIV infection: a narrative description of the Italian experience

P 28

Real Life efficacy and satisfaction of long-acting ART Cabotegravir-Rilpivirine: new era of ART

P 29

Bictegravir versus Dolutegravir-based regimen in the setting of Rapid ART Initiation: 48-week analysis in a one clinical center

P 30

Outcome of DRV/cobicistat-based regimens in HIV-infected people who experienced virological failure

P 31

The impact of Doravirine on lipid metabolism: a real-life study

P 32

Cardiovascular risk and ARV: an observational study of PLWH with PI based regimen versus INSTI and NNRTI based regimens

P 33

Long-acting injectable CAB/RPV vs DTG/RPV: two sides of similar two-drugs regimens

P 34

Dual therapy vs triple therapy in experienced PLWH: a multicentre one-year long observational study

P 35

Safe switch to dual therapy in HIV vertically transmitted young patients

P 36

PWH pioneers of cabotegravir and rilpivirine long-acting therapy in SCOLTA: who are they?

P 37

CD4 and CD4/CD8 ratio gain in PLWH treated with fostemsavir: results from the PRESTIGIO Registry

P 38

Clinical Trials versus Real-Life: Similarities and Differences of patients receiving LA CAB/RPV in a large clinical centre

P 39

“Test and treat strategy”: evaluation data from a multicenter Italian cohort

P 40

Antiretroviral therapy is associated with Sexual Dysfunction and paresthesias

P 41

Rescue therapy with Ibalizumab in HIV MDR patient

P 42

Analysis of determinants of c-ART switch strategies in PLWH in post-COVID-19 era: results from a real-life retrospective study from a tertiary University center in Italy

P 43

Immune reconstitution and safe metabolic profile after the switch to bictegravir/emtricitabine/tenofovir alafenamide fumarate among virologically controlled PLWH: a 96 week update from BICTEL cohort

P 44

CMV re-activation in patients on triple ART switching to B/F/TAF or DTG/3TC: a substudy of the DEBATE Trial

Poster ▸ Clinical HIV

P 45

Clinical/therapeutic correlates of anxiety and depression in people living with HIV

P 46

HBcAb positivity is a risk factor for failure to achieve complete virologic suppression of HIV-RNA after antiretroviral switch to 3TC+DTG

P 47

Prevalence and risk factors for sleep disturbances in PLWH: preliminary results from an observational study

P 48

Impact of SARS-CoV2 pandemic on immune, viral and metabolic status in an Umbrian PLWH cohort

P 49

Cerebrospinal fluid drain infection caused by pandrug-resistant Staphylococcus epidermidis treated with ceftaroline in combination with fosfomycin and vancomycin in a PLWHIV with AIDS-defining illness

P 50

A Case of Central Nervous System Infection Diagnosed as Frontotemporal Dementia

P 51

Cardiovascular safety of doravirine/lamivudine/tenofovir disoproxil fumarate in a cohort of virologically suppressed PLWHIV

P 52

Aging and HIV: between gaps and perspectives

P 53

Study of a novel combination of immunovirologic and genetic parameters in early-treated HIV-1 patients undergone to antiretroviral therapy interruption (ATI) aimed at defining an algorithm predictive of post‐treatment control (PCT)

P 54

Viro-immunologic pre-treatment predictors of suboptimal viral suppression at 48 weeks of antiretroviral therapy

P 55

Cryptococcal meningitis as the first clinical presentation of HIV infection

P 56

Prognostic factors of CD4 recovery after 12 months of treatment in a cohort of HIV-1 positive patients

P 57

Survival of HIV/HCV co-infected individuals received liver transplantation in the post-DAA era in Modena

P 58

Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort

P 59

Toxoplasmosis mimicking CMV chorioretinitis in newly diagnosed PLWH: a case report

P 60

Tubercular rhombencephalitis and ocular syphilis, with possible central nervous system compartimentalization, in a newly diagnosed AIDS patient

P 61

Identikit of the HIV patient with acute pathology: epidemiology and clinical characteristics of HIV patients hospitalized in the last year in an Italian University Hospital

P 62

A case of PCP in a patient with undiagnosed HIV infection

P 63

An unusual increase in Kaposi Sarcoma diagnosis in naïve PLWH in the last year in our area. Did the doctors forget this cancer or is it just another late gift of the pandemic?

P 64

Reasons for long-acting treatment refusal despite eligibility in a cohort of people living with HIV

P 65

Progressive disseminated histoplasmosis in patients living with HIV: case series and review of literature in non-endemic areas

P 66

A case of HIV-2 infection in an African man resident in Italy for a long time

P 67

P 68

The two sides of doravirine-based regimens: a descriptive study focusing on kidney function and lipidic profile

P 69

Serodiscordant twins: a case report of vertical HIV trasmission and a minireview of the literature

P 70

Extracerebral toxoplasmosis in AIDS: a rare case of T. gondii myositis

P 71

Varicella-zoster virus is an important but often forgotten pathogen in people living with HIV

P 72

Should echo-doppler of the supra aortic vessels be considered as a screening test in all patients or only in those with a significant cardiovascular risk prediction by Framingham score?

P 73

Next generation sequencing in the HIV-infected naive patient: a single centre performance evaluation

P 74

Demographical, clinical, and immunological characteristics of c-ART naive patients and risk factors of advanced disease across the years: preliminary results from a tertiary University hospital in Italy

P 75

Characterization and role of HIV-DNA minority mutations in a long-term treated paediatric patients cohort

P 76

Evaluation of the clinical presentation of naïve HIV patients in the pre-Covid era vs those enrolled in the Covid era: data from a Neapolitan multicenter cohort

P 77

Management and outcome of pregnancy in HIV-infected women in a northern Italian hospital

Poster ▸ Comorbidities

P 78

Incidence and outcome of TB/HIV co-infection in a rural area of Senegal: a 13-year retrospective study

P 79

Prevalence and type of sleep disturbances in a modern cohort of people living with HIV

P 80

Improvement in insulin sensitivity after the switch from dolutegravir/lamivudine or bictegravir/emtricitabine/tenofovir alafenamide to doravirine/tenofovir disoproxil fumarate/lamivudine in HIV-infected patients with weight gain

P 81

Complete remission of polyarteritis nodosa using etanercept in a HIV positive patient: a case report

P 82

Liver fibrosis assesment by fibrosis4 index and correlation with cardiovascular risk in people living with HIV

P 83

Metabolic, hormonal, vascular and psychological characterization of Erectile Dysfunction in young man living with HIV: preliminary results of a cross-sectional ongoing study

P 84

Sleep disorders and antiretroviral therapy: a real-life study

P 85

Erectile Dysfunction in young men with vertically acquired HIV infection: a retrospective study

P 86

Polypharmacy and aging in people living with HIV: 6 years of experience in a multidisciplinary outpatient clinic

P 87

Evaluation of lipid profile and intima media thickness in HIV experienced patients treated with PI-based regimens vs PI-sparing regimens

P 88

Vertebral osteomyelitis from Mycobacterium avium complex in ID acquired, six years after immunological recovery

P 89

Liver enzyme variation after switching to Emtricitabine/Tenofovir Alafenamide/Bictegravir is associated with Glucose increase in a real-life cohort

P 90

Weight gain in PLWH: role of multidisciplinary approach

P 91

Correlating Qualitative/Quantitative Quantiferon- Tb Gold Plus Results And Cd4+/Cd8+ Count: A Retrospective Study In A Hiv Cohort

P 92

Is CAP (Controlled Attenuation Parameter) a useful test in the management of older HIV positive patients?

P 93

Psychological well-being in a cohort of people living with HIV: a single center study

P 94

NAFLD In People Living With HIV (PLHIV): risk factors associated with steatosis confirmed by fibroscan

P 95

Correlation between bone and miointimal damage in patients with HIV

P 96

A Nocardia From Nowhere

P 97

Salmonella enteriditis spondylodiscitis in a liver transplanted HIV-HBV-HCV-HDV patient: a case report

P 98

Not all that's indolent can't hurt: an aggressive case of EBV-positive mucocutaneous ulcer (EBVMCU) in an HIV naive patient

P 99

A multidisciplinary approach for an uncommun case of infective endocarditis

P 100

The impact on body weight and body mass index of glucagon-like peptide 1 receptor agonists in diabetic people living with HIV

P 101

Cancer in People Living With HIV: study of the outpatient population at Tor Vergata Hospital

P 102

Cancers of the skin and mucous membranes in HIV-infected patients compared to the general population

P 103

Prevalence of metabolic syndrome in a cohort of people living with HIV: lifestyle and risk factors analysis

P 104

Efficacy and safety of dolutegravir + lamivudine in patients in onco-haematological treatment

P 105

Statins and Aspirin use in people living with HIV (PLWH): gap between European AIDS Clinical Society guidelines and clinical practice

P 106

Evaluation of intimal media thickness in HIV-experienced patients treated with triple therapy vs patients treated with dual therapy: multicenter cohort data

P 107

Peritoneal-pleural tuberculosis in a HIV positive and cirrhotic patient

P 108

Depressive disorder and vitamin D in a group of HIV patients in cART: dual therapy versus triple therapy

P 109

Male breast cancer in a patient with HIV-HCV coinfection: a case report

Poster ▸ COVID-19

P 110

Scaling up COVID 19 response among adolescents and young people in Limbe health district of Cameroon

P 111

Risk of hospitalization and sequelae in patients with COVID-19 treated with 3-day early remdesivir vs. controls in the vaccine and Omicron era: a real-life cohort study

P 112

Prognostic value of creatinine levels at admission on disease progression and mortality in patients with COVID-19. An observational retrospective study

P 113

Long-covid characterization in a cohort of patients from Campania: prospective cohort study results

P 114

Risk factors for acute kidney injury (AKI) in patients hospitalized with COVID-19: results of a retrospective cohort study

P 115

The impact of co-infections and antibiotic use in SARS-CoV-2 hospitalized patients at Policlinico Tor Vergata Hospital, Rome, Italy

P 116

Predictors of SARS-CoV-2 infection in treatment-experienced PLWHIV: case-control study

P 117

Delta variant as a strong predictor of long COVID incidence and neuropsychiatric symptomatology: data from a large, multicenter, prospective cohort study

P 118

Impact of COVID-19 on the long-term outcome among PLWH: a real-life study

P 119

COVID-19 in immunocompromised patients: what is the role of passive and active immunisation?

P 120

Factors associated with anti-spike SARS-CoV2 antibody titer among patients hospitalized with COVID-19-related pneumonia

P 121

Epidemiological and clinical factors related to late negativization of SARS-CoV 2 swab

P 122

Early treatment of COVID-19 in out-patient setting: a single-center retrospective study

P 123

Glucocorticoids in diabetic COVID-19 patients: efficacy and safety of Deflazacort

P 124

Post-COVID-19 Syndrome: a retrospective study of our center's patients

P 125

Impact of SARS-CoV2 infection in PLWH in the vaccine era

P 126

Incidence and burden of long COVID in Africa: a systematic review and meta-analysis

P 127

Vaccination against SARS-CoV2: are antibodies predictive of protection?

P 128

Survival stratification according to soluble urokinase plasminogen activator receptor (suPAR) levels of COVID-19 hospitalised patients

P 129

Does remdesivir affect renal function in SARS-CoV2 infected patients? Real life data in a single center in Perugia

P 130

Which is the efficacy of Sotrovimab in reducing disease progression and death during the Omicron era? Answer from a real-life study

P 131

Treatment with nirmatrelvir/ritonavir prevented hospitalizations and deaths in patients diagnosed with COVID-19 at a residential care facility in Milan, Italy

P 132

Oldest old outpatients with mild-moderate SARS-CoV-2 infection treated with monoclonal antibodies: a real life single center study

P 133

Relationship between ultrasensitive SARS-CoV-2 viraemia, inflammatory parameters and lymphocyte stimulation test

P 134

SARS CoV 2 infection in a patient affected by cerebral amyloid angiopathy: case report and literature commentary

P 135

Remdesivir-nirmatrelvir combination: in vitro activity and a case report

P 136

Correlation between IgM and IgG anti-Sars-Cov-2 and clinical Covid stadiation

P 137

Immunogenicity of primary two dose cycle and three dose of mRNA vaccine in treated solid cancer patients

P 138

Clinical efficacy of two doses of mRNA-based vaccines COVID-19 for solid cancer patients on treatment

P 139

Incidence of Post-COVID conditions in people treated with monlupiravir: a single-center experience

P 140

SARS-CoV-2 infection and solid organ transplant recipients: a single center experience

P 141

Keystone bacterial species of altered blood and oral microbiota profile during SARS-CoV-2 infection

P 142

Latina score for discrimination between progressor and non progressor SARS-CoV-2 infected patients

P 143

A retrospective cohort study to understand the impact of the drugs indicated in the early treatment of Sars-CoV-2 disease and the risk of hospitalization

P 144

Impact of COVID pandemic and COVID disease on aging trajectories in older nursing homes residents in Italy

P 145

Use of a rapid molecular multiplex real time PCR test for the detection of SARS-CoV-2, influenza A/B and respiratory syncytial virus

P 146

Active metabolite of Erdosteine (MET-1) inhibits SARS-CoV-2 infection and modulates inflammatory state in A549 cells

P 147

SARS-CoV-2 infection in Chimeric Antigen receptor T cell patients

P 148

Alpha-synuclein multimer/monomer ratio is an important determinant of Type-I Interferon response against SARS-CoV-2 infection

P 149

Early SARS-CoV-2 Treatment in Solid Organ Transplant recipients: a Single-Centre Retrospective Cohort Study during the Omicron era

P 150

Characterization of the second, third and fourth wave of COVID 19 occurring in Campania: results of a cohort study

P 151

Anti-SARS-CoV-2 humoral and cellular immune responses in health care workers 4 months after a 4th vaccination with the Pfizer-BioNTech bivalent vaccine

P 152

Analysis of T cell receptor repertoire in vaccinated and unvaccinated COVID-19 patients

P 153

Risk factors of prolonged SARS-CoV-2 infection in patients with mild sympthoms, a retrospective analysis

P 154

Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5 in booster vaccinated immunocompromised patients at the Infectious Diseases Clinic of Perugia

P 155

A refine analysis on SARS-CoV-2 omicron variability in infected immunocompromised individuals

P 156

A data-driven identification of PASC clusters to predict recovery

P 157

Combination therapy to eradicate sarscov2 infection in a patient treated with CAR-T

P 158

The hypothesis of dysergic diathesis in long-COVID syndrome and in SARS-Cov2 post-vaccination reactions: preliminary data from a prospective cohort study

P 159

Active role of Telefono Verde AIDS and IST in the communication on COVID-19 pandemic in Italy

P 160

SARS-CoV-2 seroprevalence and associated factors in young people living with HIV attending Youth-friendly Health services in the Sofala province, Mozambique

P 161

Are there any differences in effectiveness between available antivirals and monoclonal antibodies treatments in paucisymptomatic SARS-CoV-2 infected patients? A real life experience

P 162

Monoclonal antibodies (mAbs) and antiviral drugs for SARS-CoV2 treatment in patients with oncohematological disease

P 163

Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and lung involvement in acute and post-acute SARS-CoV-2 infection

P 164

Risk-factors for mortality of COVID-19 in hematologic patients: a multivariate analysis in Galliera hospital COVID-19 cohort

P 165

Remdesivir 3-day course reduces the risk of disease progression in a real-life matched cohort

P 166

SARS-CoV2 infection in dialysis patients: early treatment impact on clinical outcome

P 167

Sotrovimab vs Tixagevimab/Cilgavimab in outpatients with COVID-19: Clinical practice

P 168

A comparative focus between immunocompromised and immunocompetent patients with COVID19 infection receiving early antiviral therapy in a real-world scenario

P 169

The impact of cognitive reserve on neurocognitive impairment during long-COVID-19

P 170

Recurrent COVID-19 infection in a patient with post-remission onco-haematological diseases

P 171

Is it possible to identify predictive factors for COVID-19 severe disease and mortality in the post-vaccine era? A real-life single cohort Italian experience

P 172

The impact and outcome of early treatment for COVID-19 in transplanted patients: a real life study

P 173

Risk Factors Associated with Long COVID: A Retrospective Study

P 174

Real-World Use of Sotrovimab in outpatients and hospitalized COVID-19 during Omicron pandemic wave

P 175

Sotrovimab treatment in Severe COVID-19

P 176

A SARS-CoV-2 cluster in patients with onco-hematological disease

P 177

SARS-CoV-2 infection in oncohematological patients: a real-world experience

P 178

Characterization and monitoring of post-acute sequelae of SARS-CoV-2 infection (PASC) through a voice assistant platform: an ecological prospective study

P 179

Importance of use of antiviral and monoclonal therapies in patients at risk of developing severe disease and complications from SARS-CoV2 infection: experience of COVID-DH of Pescara Civil Hospital

P 180

The clinical management of fully vaccinated patients at high risk of disease progression with symptomatic COVID-19 infection at ASST Lecco: Real-life experience

P 181

Evaluation of the immune response to SARS-CoV-2 vaccination one year after the booster dose in oncology patients

P 182

SARS-CoV-2 infection in patients with haematological malignancies: in search of lost timing?

Poster ▸ Epidemiology and Prevention

P 183

Convenient&Quick - Let's do it in Pharmacies

P 184

Sexually Transmitted Infections’ (STIs) screening offered by not-for-profit sector entities during the COVID-19 pandemic: a descriptive observational study of the population accessing a LGBT+ dedicated service

P 185

The future impact of SARS-CoV-2 on sexually trasmitted diseases spread

P 186

Human papillomavirus vaccine uptake before and after the implementation of an on-site vaccination service at an HIV clinic in Milan, Italy: a retrospective observational study

P 187

Incidence of HCV and HIV in the female prison population: Analysis of two Italian centers

P 188

Detection of asymptomatic Mpox virus infection in high-risk men who have sex with men: a prospective analysis

P 189

Life expectancy and determinants of increased risk of death in PLWH

P 190

Use of MVA-BN vaccine in the context of the current Mpox outbreak: early experience of an infectious and tropical diseases unit in Florence, Italy

P 191

Outbreak of HIV among people who inject drugs discovered through phylogenetic analysis: are we seeing just the top of the iceberg?

P 192

Evaluation of the acceptance of salivary rapid HIV tests in the IDU population afferent to the Ser.D. of Treviso

P 193

Lack of antibody protection for HBV in young people undergoing non-occupational Post-Exposure Prophylaxis (PEP) for HIV in a large tertiary hospital in Milan, Italy

P 194

High Prevalence of HIV Infection and Late Diagnoses by HIV indicator conditions guided screening in the Emergency Department: Preliminary Results from the INDI Study

P 195

Highlights from an ongoing anal cancer prevention protocol for people living with HIV at the Infectious and Tropical Diseases Unit of Padua University Hospital

P 196

Strategies to reduce vaccine hesitancy. First step: know your population. A single center in-depht analysis of PLWHA adherence to vaccination schedule

P 197

Retrospective analysis of accidental and occupational exposures, post-exposure prophylaxis (PEP) prescription and surveillance program in a large Hospital, Northern Italy

P 198

HPV vaccination coverage in MSM living with HIV: a retrospective monocentric study in Northern Italy

P 199

Do we think enough about strongyloidiasis, schistosomiasis and Chagas disease among HIV-positive migrant patients? Screening ratio and seroprevalence in a tertiary health-care center in Italy

P 200

Monkeypox vaccination in a cohort of people on pre-exposure prophilaxis (PrEP) or living with HIV infection (PLWH): a retrospective observational study from the Umbria region, Italy

P 201

HIV Testing in the Emergency Department: an effective strategy to increase new diagnoses

P 202

HPV vaccination days in HIV and STI outpatient clinic

P 203

Missed opportunities in HIV diagnosis: to recognize sentinel conditions for HIV to reduce late presentation in an urban setting in northern Italy

Poster ▸ Hepatitis and other viral infections

P 204

An Occult hepatitis B virus Infection Reactivation in an HIV/HCV Coinfected patient during an Immune Reconstitution Inflammatory Syndrome

P 205

Human Orf: an under-recognized and under-reported viral infection

P 206

Evaluation of the effectiveness of a population-based health policy to increase HCV treatment coverage: an interrupted time series analysis

P 207

Evaluation of anti-Mpox IgG development in infected patients

P 208

Performance evaluation of HIV-2 RNA plasma quantification using a commercial RUO RT-PCR assay

P 209

Inheritehd chromosomally integrated HHV6: a case report

P 210

Early HCV treatment during RCHOP therapy in subjects with non Hodgkin lymphoma

P 211

Hepatic flare and immune reconstitution in Hepatitis B Virus-Human Immunodeficiency Virus coinfected patients

P 212

Tuscany Region: Epidemiology of Hepatitis C

P 213

Patient with HCV/HBV-related cirrhosis and colon cancer: a difficult patient to treat

P 214

Pathways underlying HDV persistence act independently from the extent of HBV resevoir and are sustained by an abundant production of HBsAg derived from integrated HBV-DNA

P 215

Kinetics of the three HBsAg isoforms along with HDV-RNA predict virological response in CHD patients treated with bulevirtide up to 96 weeks

P 216

Identification of novel molecular targets for therapeutic reconstitution of HBV-specific CD8 T cell reactivity in chronic hepatitis B virus infection

P 217

Ecthyma gangrenosum with facial and oral localization in a young neutropenic woman with recent Dengue infection

P 218

HCV relapse after sofosbuvir/velpatasvir/voxilaprevir in a patient with chronic lymphocytic leukemia: speculations on a potential cause

P 219

Preliminary results of a Case Finding and Linkage to Care program for high-risk HCV infected individuals

P 220

Long-term mortality after HCV eradication among PLWH

P 221

A pilot intervention for HCV elimination among MSM in Rome: results from a program of micro-elimination of HCV

P 222

Integration of hepatitis C and addiction treatment in people who injects drugs. The San Patrignano HCV-free and drug-free experience

P 223

Acute viral hepatitis from HBV due to immune-reconstitution in a patient with pleural tuberculosis receiving treatment

P 224

A case of congenital CMV infection due to pre-conceptional maternal primary infection: serologic pitfalls in Valacyclovir Era

P 225

Anti-HBV therapy in hemodialytic patient: a not easy approaches

P 226

Prevalence of HDV infection in HBV positive patients from University Hospital in North Sardinia. Updated data

P 227

Acute HBV hepatitis leading to liver failure: when to treat?

Poster ▸ Immunopathogenesis and Vaccines

P 228

High frequency of type I Interferon autoantibodies in a cohort of middle-aged people with HIV: a retrospective pilot study

P 229

Viral blips and virologic failures following mpox MVA-BN vaccination among people living with HIV

P 230

How COVID-19 asymptomatic infection influence response to BNT162b2 vaccine among Persons Living with HIV (PLWH): data from patients in charge at Cotugno Hospital, Naples, Italy

P 231

Gut microbiome influences the reservoir in acute, cART-treated HIV

P 232

Association between SARS-CoV-2 RNAemia and systemic inflammation in people with HIV hospitalized for acute COVID-19 pneumonia

P 233

Heavily Treatment-Experienced (HTE) People Living with HIV (PLWH) with Vertical Transmission and Detectable Viremia do not Display Increased Peripheral Inflammation Markers: Data from the Prestigio Registry

P 234

Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience

P 235

Determinants of recorded SARS-CoV-2 vaccine uptake among ART-compliant people living with HIV

P 236

Targeting Nef as the Primary Driver of HIV Persistence and Immune Escape

P 237

Tolerability of Shingrix in patients with multiple sclerosis and other neurological diseases on immune modulating treatments

P 238

Antibody response to the third dose of SARS-CoV-2 mRNA vaccine in PLWH on ART at 12 months after its administration

P 239

Immunological and inflammatory profile of cerebrospinal fluid (CSF) and plasma of people living with HIV (PLWH) with or without Central Nervous System (CNS) involvement

P 240

Herpes zoster prevention through administration of recombinant zoster vaccine (RZV) in a cohort of PLWH in Rome

P 241

Serum and Plasma Biomarkers of Central Nervous System Involvement Measured Through Single Molecule Array in PLWH and controls

P 242

Immunization coverage in older people living with HIV in a large Hospital, Northern Italy

P 243

Immune responses to vaccination in HIV vertically-infected patients: a long term evaluation

P 244

Compliance with immunisation amongst HIV-infected patients and clinicians vaccines offer rates in the HIV Outpatient Clinic of the Valle d’Aosta Region

P 245

The impact of HIV-1 infection and sexual orientation on the intestinal microbiota composition in HIV-1 serodiscordant couples

P 246

Idiopathic CD4 Lymphocytopenia: novel insights into the immunological functions of CD4 T cells

Poster ▸ PrEP

P 247

Chemsex in PrEP users of a community-based center PrEP Point Plus (PPP)

P 248

The Anlaids forum may identify new subjects to be addressed for PrEP

P 249

Pre-Exposure Prophilaxis (PrEP) usage in a MSM adult population: organizational procedures, issues and observations

P 250

High Propensity to Switch to Long-acting Injectable PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men

P 251

Is hypophosphatemia a real contraindication for PrEP? Let’s ask the renal tubule

P 252

Pre-exposure prophylaxis (PrEP): achieved results and what remains to be done

P 253

High interest in long-acting injectable cabotegravir (CAB-LA) among “on demand” PrEP users

P 254

PrEP in Eastern Piedmont: STIs and renal safety

P 255

Reasons for leaving a PrEP community-based service: our experience in Bologna, Italy

P 256

A descriptive analysis of serum creatinine variation in users assuming TDF-PrEP: a possible role of age and comedication

P 257

Pre-exposure prophylaxis for HIV and risk of recurrent sexually transmitted infections

Poster ▸ Social and behavioural science, marginalized groups, community aspects and community surveys

P 258

Impact of peer education on sexual health knowledge among adolescents and young persons in the Buea subdivision of the South West region of Cameroon: through VCT campaigns

P 259

Chems & le Holograms

P 260

THE. M.A.NNA project ( Maometto Alla moNtagNa)

P 261

Young people and HIV - Millennials on HIV/AIDS/STI and emerging needs

P 262

Bringing HIV prevention to schools: data analysis

P 263

The non-Italian MSM population within the Rome Checkpoint HIV and STD screening context

P 264

IO C(‘)ENTRO HIV CheckPoint in Genova, Italy: results of first year experience towards future objectives and new operational strategies

P 265

Things change. Latest U=U communication campaign of LILA Cagliari

P 266

Supporting Quality of Life: complexities and goals in the experience of a Mindfulness group in a community site

P 267

One year experience of the Ancona Checkpoint: first analysis of COBATEST data of population

P 268

Prisoners living with HIV. Retrospective analysis the cascade of care in two penitentiaries in Northern Italy

P 269

Fifth year of mono symptomatic therapeutical group for chemsex addiction, a roundup

P 270

Mapping the Status of Services in the Field of Sexual Health and HIV Management in Thirty-One Provincial Capitals of Italy

P 271

Taking it to the Streets: HIV Prevention for Drug Users through Outreach Units in Rome in 2022

P 272

Breaking barriers to HIV and HCV screening among migrants in Rome

P 273

Transgender and HIV: a case for an inclusive clinical record

P 274

U=U. Cosa sai, cosa non sai

P 275

LILA testing services in 2022: observations from experiences of our network

P 276

The Relationship as Outcome Indicator: Person-Based Approach in Rome

P 277

“Resilience” – Study on the psychological and practical impact of COVID-19 on the quality of life of people living with HIV

P 278

Conscious sexuality and young people: let's talk about HIV

P 279

How much does stigma weigh in a more informed setting? An online survey

P 280

Difficult to reach, fragile key populations at high risk: the Bergamo Leaves No One Behind Project

P 281

The two faces/directions of the Bergamo Check Point: young people and key populations

P 282

Foreigners and their requests to LILA helpline from 2018 to 2022: a comparative analysis

P 283

NO ONE LEFT BEHIND - Omphalos LGBTI+ experience, Perugia, Italy. A community-based HIV testing before and after the challenging covid-19 pandemic period (2020). It's time to strengthen the dialogue about sexual health

P 284

To drink or not to drink. Data from real life and implication for dietitian counselling for PLWHA

P 285

Association between Locus of Control, Health Locus of Control, Coping and Resilience in an Italian cohort of people living with HIV

P 286

The role of emotion dysregulation in patient health engagement and HIV-related symptom distress in an Italian cohort of people living with HIV

P 287

Searching for HCV infection: involvement of Therapeutical Communities is mandatory!

P 288

HIV and HCV awareness and knowledge among the general population in Brescia, Northern Italy

P 289

Late-presenter person living with HIV in detention institute. Case report

P 290

A friendly, rapid testing and counseling approach to improve linkage to care: a two year experience at Checkpoint and Hospital center

P 291

Comprehensive Sexuality Education (CSE) in Italian secondary schools: preliminary results of EduForIST2 pilot activity

P 292

Web Listening to identify the information needs of different targets and detected the barriers to the modification of the HIV behaviors

P 293

Impact of COVID-19 on the management of their disease in People living with HIV: preliminary results of semi-structured interviews

P 294

The role of the psycho-social team of the C.A.M.A. ODV, in 25 years of activity in the "Home treatment of people suffering from AIDS and related pathologies" - Interventions in implementation of the Presidential Decree 09.14.1991 and Ministerial Decree 09.13.1991

P 295

The prevention of Sexually transmitted infections (STIs) in new migrant populations. Data from the Perugia Outpatients Clinic

P 296

Quality of pre- and post-COVID-19 healthcare: the point of view of women living with HIV

Poster ▸ STIs, Sexually transmitted infections

P 297

Ureaplasma urealyticum: a controversial pathogen to treat. The experience from a difficult-to-reach population

P 298

Reduction of sexual risky behavior and vaccination do not explain decreased incidence of Mpox among PrEP users attending a community-based facility

P 299

Monkeypox in a woman with HIV infection: a case report

P 300

Doxycycline oral treatment for latent syphilis: evaluation of outcomes and tolerability

P 301

Luetic infection in the present day: characteristics of a cohort of patients diagnosed with syphilis in the Roman suburbs

P 302

Prevalence of Human Papillomavirus (HPV) in the Oral swabs of patients at University Hospital of Bari

P 303

Prevalence of seven sexually transmitted pathogens in oral cavity and the impact of a new dedicated ambulatory for STI and Pre-Exposure Prophylaxis (PrEP) in Bari

P 304

Neisseria meningitidis in PrEP users: sexual transmission and isolation of an ESBL positive strain

P 305

HIV and Syphilis rapid tests among University students: a prevention and awareness campaign towards sexually transmitted infections

P 306

Distinct mucosal Interferon response to MPXV, HIV and HPV infections in anal cells from MSM

P 307

Rapid increase in syphilis diagnoses in Rome during the first quarter of 2023

P 308

When it rains, it pours: early treatment with tecovirimat of myopericarditis associated with monkeypox infection in a person with HIV and previously undiagnosed Lyme disease

P 309

Neisseria gonorrhoeae in a localized septic arthritis: an unusual aetiology

P 310

Analysis of STIs incidence and risk factors in a cohort of MSM attending a PrEP community-based center and the STD outpatient clinic of the Dermatology Department of S.Orsola-Malpighi Hospital in Bologna. One year follow-up data from SEX-CHECK-PLUS study

P 311

Syphilis in PrEP users and PLWH attending an outpatient clinic of a large clinical centre in Rome

P 312

A case of otic involvement in secondary syphilis

P 313

Case Report: A novel presentation of Neurosyphilis in a HIV-uninfected patient with fronto-temporal-parietal cerebral atrophy

P 314

Effectiveness of the mpox vaccination campaign and vaccine safety profile – experience of a STI clinic during 2022 epidemic

P 315

The impact of COVID-19 pandemic on STI trends and at-risk sexual behaviors. A national multicenter study

Poster ▸ Virology and Pharmacology

P 316

Extensive virologic characterization in an HIV-infected individual with apparent HIV remission for 2 years after allogeneic stem cell transplantation with CCR5 wild-type cells: a case study

P 317

Safety evaluation of cabotegravir in zebrafish embryos

P 318

Effect of doravirine on dolutegravir trough concentrations in people with HIV switched from darunavir/cobicistat

P 319

Single-cell transcriptomics of CSF and PBMC in a primary HIV infection of a subject already affected by multiple sclerosis

P 320

Use of HIV genotype resistance test in Italy: a national survey

P 321

Evaluation of ELITE InGenius® integrated system for detection, quantification and monitoring of HIV-1 RNA in Cerebrospinal Fluid

P 322

Comparison of developmental safety between doravirine and efavirenz in zebrafish (Danio rerio) embryos

P 323

Large proportion of new HIV diagnoses in Northern Italy sustained by non-B subtypes with higher HIV DNA in the Effector Memory subset

P 324

Does proviral DNA-NGS match historical genotype?

P 325

The effects of cognate peptide recognition on proviruses in expanded T cell clones in an Elite Controller

P 326

HIV Drug Resistance: Sanger Sequencing versus Next Generation Sequencing

P 327

A novel NanoBRET protease sensor to sense HIV-1 PR activity in living cells

P 328

Evaluation of a new automated real-time PCR commercial test for HIV-DNA quantification in PBMC and whole blood samples

P 329

Evaluation of the HIV1 ELITe MGB assay for HIV-1 RNA quantification: comparison with the COBAS HIV-1 test

P 330

Ritonavir-boosted atazanavir dose escalation to overcome the drug-drug interaction with rifampicin: effectiveness on intracellular and plasma drug concentrations

P 331

The application of HIV-1 genotype resistance test: a multicentre Italian virology laboratory experience

| Privacy policy | Cookies policy | Termini e condizioni di utilizzo |

P. IVA 10756900154